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Abstract
Our laboratory demonstrated that a natural human serum antibody, sHIgM12, binds to neurons in vitro and promotes
neurite outgrowth. We generated a recombinant form, rHIgM12, with identical properties. Intracerebral infection with
Theiler’s Murine Encephalomyelitis Virus (TMEV) of susceptible mouse strains results in chronic demyelinating disease with
progressive axonal loss and neurologic dysfunction similar to progressive forms of multiple sclerosis. To study the effects of
rHIgM12 on the motor function of TMEV-infected mice, we monitored spontaneous nocturnal activity over many weeks.
Nocturnal behavior is a sensitive measure of rodent neurologic function because maximal activity changes are expected to
occur during the normally active night time monitoring period. Mice were placed in activity boxes eight days prior to
treatment to collect baseline spontaneous activity. After treatment, activity in each group was continuously recorded over 8
weeks. We chose a long 8-week monitoring period for two reasons: (1) we previously demonstrated that IgM induced
remyelination is present by 5 weeks post treatment, and (2) TMEV-induced demyelinating disease in this strain progresses
very slowly. Due to the long observation periods and large data sets, differences among treatment groups may be difficult
to appreciate studying the original unfiltered recordings. To clearly delineate changes in the highly fluctuating original data
we applied three different methods: (1) binning, (2) application of Gaussian low-pass filters (GF) and (3) polynomial fitting.
Using each of the three methods we showed that compared to control IgM and saline, early treatment with rHIgM12
induced improvement in both horizontal and vertical motor function, whereas later treatment improved only horizontal
activity. rHIgM12 did not alter activity of normal, uninfected mice. This study supports the hypothesis that treatment with a
neuron-binding IgM not only protects neurons in vitro, but also influences functional motor improvement.
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Introduction
Long-term monitoring and analysis of neurological function in
rodent disease models remains a challenge. Nocturnal behavior is a
sensitive measure of rodent neurologic function because maximal
activity changes are expected to occur during the normally active
night time monitoring period [1]. However, in animal models of
slowly progressive diseases performance monitoring often extends over
several weeks. We previously reported that oligodendrocyte-binding
antibody (rHIgM22) enhanced remyelination by 5 weeks after the
treatment [2]. Taken together that both the evolution of disease and
repair is a slow process and to assure that any fluctuation in activity is
taken into account, we monitored prolonged activity with the same
sampling density used in short-term monitoring. This created large
and highly fluctuating data sets (Figure 1A-C). To clearly delineate
post-treatment changes and recover general trends in long-term
activity, we compared the use of data binning, Gaussian filtering, and
polynomial fitting by using Mathematica (Wolfram Research, Inc.).
Intracerebral infection with Theiler’s Murine Encephalomyelitis
Virus (TMEV) of susceptible mouse strains results in chronic
demyelinating disease with progressive neurologic dysfunction
similar to progressive forms of multiple sclerosis [3]. Treating this
model with IgM class antibodies that bind to oligodendrocytes
improves CNS remyelination [4]. In contrast, a serum-derived
human monoclonal antibody (sHIgM12) that binds to neurons,
promotes robust neurite outgrowth to the same degree as laminin,
and reduces the inhibitory effects of CNS myelin on neurite
outgrowth [5]. More recently a recombinant form of human
sHIgM12 was generated (rHIgM12) with identical biological
properties. We showed previously that rHIgM12 has a half-life of
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nervous tissues (unpublished observation). To study the effects of
rHIgM12 on the activity of TMEV-infected mice we monitored
spontaneous activity over several weeks using AccuScan activity
boxes (Accuscan Instruments, Inc., Columbus, OH). We chose a
relatively long 8-week monitoring period for two reasons: (1) IgM
Figure 1. Example of spontaneous nocturnal activities of TMEV infected mice. A) Original complete recordings of horizontal activity over
the period of 64 days. High nocturnal and low diurnal activities are easy to appreciate. Because mice are normally active during the night time we
selected nocturnal activities for analysis (6PM-6AM). However, by visual inspection of unfiltered compressed recordings in either horizontal (B) or
vertical (C) activity it may be difficult to identify real long-term changes.
doi:10.1371/journal.pone.0026001.g001
Table 1. Length of the spontaneous activity monitoring in published studies compared to current study.
Publication Length of recorded locomotor activity session
Mikami et al. 2002, 2004 [14,15] 10 minutes (10 minutes of habituation)
Melnick and Dow-Edwards 2001 [16] 60 minutes (no habituation)
Chen et al. 2005 [17] 30 minutes (no habituation)
Torres-Reveron and Dow-Edwards 2006 [18] 60 minutes (20 minutes of habituation)
Zhu et al. 2007 [19] 60 minutes (no habituation)
Li et al. 2009 [20] 3 hours (1 hour of habituation)
(Rivera-Quinones et al. 1998; McGavern et al. 1999 [1,21] 3 days (no habituation)
Current Study 64 days (8 days of habituation)
doi:10.1371/journal.pone.0026001.t001
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(2) TMEV-induced demyelinating disease in this strain progresses
very slowly compared to the purely autoimmune EAE models of
MS [6]. Due to the long observation periods compared to
previously published studies (Table 1), identifying changes by
visual inspection of raw data proved difficult.
Materials and Methods
Mice
SJL/J mice (Jackson Laboratories, Bar Harbor, ME) were
housed and bred in Mayo Clinic’s animal care facility. Animal
protocols were approved by the Mayo Clinic Institutional Animal
Care and Use Committee.
Theiler’s virus model of demyelination
Demyelinating disease was induced in 6- to 8-week-old female mice
by intracerebral injection of TMEV. A 27-gauge needle delivered
10 ml containing 2.0610
5 plaque-forming units of Daniel’s strain
TMEV. This resulted in .98% incidence of infection with rare
fatalities. All animals developed mild encephalitis, which resolved
within 2 weeks. Animals worsen over the next 6–8 months with chronic
spinal cord demyelinating disease. Axon injury and loss begin three
months after infection correlating with neurologic dysfunction [3].
Antibody Treatment
SJL mice (uninfected, 45 and 90 days post infection) were
treated with a single 200 mg intraperitoneal dose of antibodies
Figure 2. A single i.p. dose of neuron-binding antibody (rHIgM12) improves horizontal activity in chronically infected SJL mice.
Three groups of 5 SJL mice at 90dpi were placed in AccuScan activity monitoring boxes. Baseline measurements were collected over 8 days. After the
treatment mice were monitored continuously over 8 weeks. Panels A, C and E correspond to horizontal activity and B, D and F correspond to vertical
activity. A, B) Average nocturnal activities presented as bins for each day suggested the improvement in horizontal activity only in rHIgM12-treated
group; C) Gaussian filtering (GB=2 days) and E) 6
th order polynomial fitting of standardized Z-values provided a clear and distinct improvement in
rHIgM12-treated mice. B, D and F) Vertical activity was not affected by any treatment. Activity (vertical scale) is the number of beam interruptions per
hour. Parameter GB can be interpreted as a value (in days) of the filter half width at the half height. With the increase of GB value the standard
deviation decreases. The pointwise 95% confidence bands are given for each day.
doi:10.1371/journal.pone.0026001.g002
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Third group was treated with 0.5 ml PBS only.
Spontaneous activity monitoring
Spontaneous locomotor activity was recorded with Digiscan
open field (OF) apparatus (Omnitech Electronics; Columbus, OH)
and Versamax software, v.4.12-1AFE (Accuscan Instruments, Inc.,
Columbus, OH). The apparatus consists of six acrylic cages
(40640630.5 cm) supported by a metal frame that holds two sets
of photo cells. The device measures the number of discrete
horizontal and vertical movements by tabulating the number of
projected infrared beam interruptions. In all cages mice were
exposed to identical environmental conditions: (a) freely accessible
food and water, (b) a normal 12 h light/dark cycle, (c) 70uF
ambient temperature. In each experiment hyperactive and, in rare
occasion, overweight animals were excluded and the remainder of
mice were randomized. Several groups of 5 SJL mice were placed
in the center of the each cage and the baseline spontaneous activity
was collected over the period of 8 consecutive days. After this
period, three groups of mice with the most similar baseline activity
were treated with rHIgM12, control IgM antibody or saline and
then monitored over the period of 8 weeks. Data was collected as
number of beam breaks per 1-hour blocks. The total horizontal
and vertical activities were recorded using Versadat program,
v.3.02-1AFE (Accuscan Instruments). We could not put more than
5 animals per activity box because this is the maximal number of
animals allowed by Institutional Animal Care and Use Committee
(IACUC).
Data Analysis
Differences among treatment groups may be difficult to
appreciate studying original unfiltered recordings (Figure 1A–C).
To recover slow trends in the highly fluctuating original data we
applied three different methods: 1) binning, 2) application of
Gaussian low-pass filter (GF), and 3) polynomial fitting.
Data binning is the simplest method and replaces a group of
data points within a preselected bin by their average value. In our
case, we selected a nocturnal bin given that murine activity peaks
at night. Therefore, we replaced all nocturnal readings (12 h/day)
by their average value as shown in Figures 2A, 2B, 4C, 4D, 6C and
6D. Comparison of groups can be performed by a simple t-test for
a difference of means, with an effective sample size of 12 hours per
treatment. Whereas these comparisons are simple, the small
sample size at each time point results in large standard errors and
statistical comparisons are of limited use. Overall, data binning is
an effective method for visualizing noisy data, but is of limited use
for statistical testing.
Gaussian filtering (GF) (also known as low-pass filtering, data
smoothing, or sensitivity enhancement) is a noise-reduction
procedure commonly used in Fourier transform spectroscopy
and image processing [7]. GF, performed with an appropriate
selection of Gaussian broadening (GB, in days) filtered out high-
frequency fluctuations at a desired level. The filter choice is
arbitrary and may be guided by the rate of expected activity
changes. GF is a smoothing method using information from points
taken from both sides of a value and weighting the influence of
these points such that influence fades according to the Gaussian
function. Computationally, GF can be implemented in two
equivalent ways: 1) Fourier transformation (FT) of the data,
followed by multiplication with a Gaussian function and inverse
FT of the product; and 2) direct convolution of the data with a
Gaussian kernel. In high-level software packages (Matlab (Math-
works) or Mathematica (Wolfram)) the Gaussian filter function is
available with minimal or no programming by the user. With
appropriate selection of GB the above detailed GF method enables
simplified visualization of highly complex and heterogeneous data.
One limitation of GF is that whereas it allows for easy visualization
of trends, statistical comparisons are complicated by the choice of
the GB.
For comparison and to demonstrate a method that allows for
simplified statistical comparison, we fit polynomials to the data.
These models allowed for polynomial terms up through the any
degree (x
n), and estimated shape parameters separately for each
treatment group (interaction terms). Our choice of a 6
th degree
polynomial was arbitrary after exploring several options, but
allowed sufficient flexibility to model non-linear effects over time.
Because the different treatment groups were optimally fit using
varying order polynomials, we chose to allow for the higher order
flexibility. Akaike Information Criteria (AIC) was used to
determine the ‘‘best fit’’ of polynomial lines across several of the
treatment groups [8]. AIC is a method of model comparison which
balances the gain in R
2 by adding additional terms, but penalizes
Figure 3. Comparison of three treatments at 90dpi by using
predicted model values. Statistical analysis was performed for each
day before and after the treatment. Horizontal nocturnal activity of
rHIgM12-treated mice as compared to control IgM- and saline-treated
mice significantly diverged/improved on day 7 (p=0.045) and day 11
(p=0.042) post-treatment, respectively (denoted by black arrows). The
pointwise 95% confidence bands are given for each day.
doi:10.1371/journal.pone.0026001.g003
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mice at 45dpi were placed in AccuScan activity monitoring boxes. Baseline measurements were collected over 8 days. After the treatment mice were
monitored continuously over 8 weeks. Panels A, C, E and G correspond to horizontal activity and B, D, F and H correspond to vertical activity. A, B)
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3
rd order fit was sufficient to capture the trend of the data, and for
some cases the 2
nd order or even the linear fit was ‘‘best’’
according to AIC. However, our primary goal was to compare
treatment groups at observed time points. Because of the large
number of data points, and because we are not using the
polynomial fit to predict (or extrapolate) treatment values outside
of our observed data, the impact of ‘‘overfitting’’ on results is
minimal.
One advantage of polynomial fitting is that the statistical
comparison of treatment groups is straightforward: treatments can
be compared at specified time points using the predicted model
values and respective standard errors. Direct pairwise comparisons
of treatments can be performed at regular intervals across the
entire time frame to determine when treatment groups have
significantly diverged. Finally, the polynomial fit removes
additional medium and low frequency noise which focuses visual
attention on the general trend over the entire time frame.
However, within each of the experiments some groups of mice
had somewhat different baseline horizontal and vertical activity (8
days). Therefore, we first used Z-values to standardize baseline
activity independently for each group and then performed
Gaussian filtering or fitted polynomials to these values.
Statistical analysis
Binning data and Gaussian low-pass filter smoothing of data
were performed by using a macro written in Mathematica
(Wolfram). Macro and instructions are available on http://
mayoresearch.mayo.edu/mayo/research/rodriguez_lab/software.
cfm. Polynomial regression models and statistical comparisons of
treatment groups were performed using the predicted model
values and respective standard errors based on the z-statistic (SAS
Institute, Inc.). Direct pairwise comparisons of treatments were
performed for each day across the entire time frame, and statistical
significance was determined at the typical a=0.05 threshold. No
adjustments were made for multiple comparisons.
Results
rHIgM12 improves horizontal activity in SJL mice when
given at 90dpi
Three groups of 5 SJL mice at 90 days post infection (dpi) were
placed in activity boxes and baseline activity was measured for 8
consecutive days. Two groups of mice were treated with a single
200 mg dose of rHIgM12 or an isotype-control IgM. The third
group was treated with saline. After the treatment, spontaneous
activity was continuously recorded over 8 weeks. Because data was
collected in 1-hour blocks, we obtained approximately 900 data
points for each group. This original, raw data (Figure 1A-C) is
highly fluctuating, so differences among treatment groups may be
difficult to appreciate. All three methods (binning, gaussian
filtering and polynomial fitting) revealed that mice treated with
rHIgM12 showed improvement in horizontal activity, whereas
control IgM- and saline-treated mice had no changes in the
activity over the period of 8 weeks (Figure 2A, C and E). Using
direct pairwise comparisons of three treatments after polynomial
fitting, we determined that improvement in horizontal motor
function in rHIgM12-treated mice became statistically significant
at day 7 post treatment (as compared to control IgM) and at day
11 (as compared to saline) (Figure 3). Observed improvement in
horizontal nocturnal activity of rHIgM12-treated animals persisted
for approximately 30 days and then returned to baseline levels.
Pairwise comparison of saline- versus control IgM-treatment
groups showed statistical significance for days 38-52. However,
when compared to major differences observed between rHIgM12-
treatment group and the controls, we believe that these differences
between the control groups are not biologically significant. On the
other hand, vertical activity did not show major differences and
was similar in all three groups (Figure 2B, D, and F).
rHIgM12 improves horizontal and vertical activity in SJL
mice when given at 45dpi
The previous study used vertical activity (rearing behavior) as a
primary readout [1]. Due to axonal dropout in chronically
TMEV-infected mice, hind limbs became progressively weak and
stiff so rearing was reduced. In the first experiment of this study,
when rHIgM12 was administered at the time of maximal
demyelination (90dpi) and onset of progressive axonal loss, only
horizontal activity was improved. The rearing behavior was not
affected and was equivalent in all three treatment groups.
Therefore we asked whether treatment at an earlier time point
may be more beneficial. In a second experiment, groups of 5 mice
were treated at 45 dpi with a single 200 mg dose of rHIgM12, an
isotype-control IgM or saline. An identical experimental design
was used; baseline activity was collected for 8 days, and post-
treatment activity for 8 weeks. In this experiment, beginning
around 2 weeks post-treatment, rHIgM12-treated mice showed
clear improvements in both horizontal and vertical activity. This
was evident after using all three methods: averaging data, applying
Gaussian filter or polynomial fitting (Figure 4C–H). Control IgM-
and saline-treated mice showed similar activity levels throughout
the end of study. In rHIgM12-treated mice, improvement in
horizontal activity was evident until the experiment ended. On the
other hand, improvement in vertical activity lasted for about 4
weeks and then dropped to baseline values. Direct pairwise
comparisons of three treatments showed that improvement in
horizontal motor function in rHIgM12-treated mice significantly
diverged at day 13 post treatment (as compared to control IgM)
and at day 9 (as compared to saline) (Figure 5A and C). Likewise,
vertical motor function in rHIgM12-treated mice significantly
diverged at day 14 post treatment (as compared to control IgM)
and at day 6 (as compared to saline) (Figure 5B and D).
Comparison of control IgM- versus saline-treated groups did not
reveal major biological differences for either horizontal or vertical
activity (Figure 5E and F).
rHIgM12 does not alter the spontaneous activity in
normal uninfected mice
Treatment with rHIgM12 in previous two experiments showed
clear beneficial effect in neurologically disabled infected mice. To
exclude the possibility that this antibody may have irritable
properties and therefore elicits increased motor function, we
performed similar experiment with uninfected mice. Three
groups of age matched uninfected mice were treated with
rHIgM12, control IgM or saline. Compared to the activity
Original, unfiltered recordings for horizontal and vertical activity; C, D) Average nocturnal activities presented as bins for each day, E, F) Gaussian
filtering (GB=2 days) and G, H) 6
th order polynomial fitting of standardized Z-values revealed improvement in both horizontal and vertical activity in
rHIgM12-treated group. Control IgM- and saline-treated groups showed similar levels of motor activity throughout the study. The pointwise 95%
confidence bands are given for each day.
doi:10.1371/journal.pone.0026001.g004
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treatments did not induce any increase in motor function of
normal mice (Figure 6). All three groups showed a tendency to
decline in spontaneous activity. This result indicates that none of
the antibodies has an influence on increasing activity in normal
mice.
Figure 5. Comparison of three treatments at 45dpi by using predicted model values. Statistical analysis was performed for each day
before and after the treatment. A, C) Horizontal nocturnal activity of rHIgM12-treated mice as compared to control IgM- and saline-treated mice
significantly diverged on day 13 (p=0.015) and day 9 (p=0.036) post-treatment, respectively. B, D) Vertical (rearing) activity of rHIgM12-treated mice
diverged/improved on day 14 (p=0.019) and day 6 (p=0.037) post-treatment, respectively. E, F) Comparisons of control IgM- vs. saline-treated mice
did not reveal major biological changes neither for horizontal (E) nor for vertical (F) activity. Black arrows denote days with onset of significant
improvement. The pointwise 95% confidence bands are given for each day.
doi:10.1371/journal.pone.0026001.g005
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groups of 5 uninfected SJL mice were placed in AccuScan activity monitoring boxes. Baseline measurements were collected over 8 days. After the
treatment mice were monitored continuously over 8 weeks. None of the treatments induced changes in either horizontal (A, C, E and G) or vertical (B,
D, F and H) activity. The pointwise 95% confidence bands are given for each day.
doi:10.1371/journal.pone.0026001.g006
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There is a critical need for the development of neuroprotective
therapies for multiple sclerosis as well as for other demyelinating
and neurodegenerative diseases. Even though there are some anti-
inflammatory drugs that may indirectly lead to a decrease in
axonal damage during inflammatory CNS disease, there are no
drugs that act directly at the level of neurons/axons. The main
goal of neuroprotection is to limit neuronal dysfunction and to
attempt to maintain the functional integrity of neurons and axons.
For many years demyelination, the pathological hallmark of MS
was considered as a cause of permanent neurological deficits. It is
clear now that demyelination is necessary, but not sufficient for
permanent axonal loss [9]. Demyelination only predisposes
denuded axons to the secondary injury caused by either T-cell
cytotoxicity or loss of local neurotrophic support from dead
oligodendrocytes [10].
Previous observation that neuron-binding antibody sHIgM12
promoted robust neurite extension [5] represents a clear beneficial
in vitro response. Because recombinant version of this antibody
showed similar in vitro properties we asked whether it would affect
motor activity of mice with TMEV-induced demyelinating disease.
Analysis of motor function was performed by monitoring the
spontaneous nocturnal activity. First, we treated mice at the time
of maximal demyelination and onset of axonal loss (90dpi). Eight
weeks after the treatment, rHIgM12 improved only horizontal
motor activity, whereas vertical activity was not affected. However,
when mice were treated earlier in the disease (at 45dpi), rHIgM12
improved both horizontal and vertical activity. In the chronic
TMEV-induced disease, rearing behavior (vertical activity) is most
severely affected and it appears that degeneration and loss of axons
responsible for this activity is irreversible. Conversely, the early
phase of the disease, when these axons are not irreversibly injured,
appears to be ideal time for the treatment. Jones et al. utilized EAE
model and by studying axonal dropout and motor function they
proposed an identical paradigm; treatment with neuroprotective
drugs should begin early in the disease, even before the onset of
motor deficits [11]. Second, because the functional improvement
occurs about two weeks after the treatment and starts to fade
approximately 25–30 days later, it may be that repeated
treatments will be necessary to sustain motor function. Unfortu-
nately in our studies, it was not possible to test multiple doses of
human IgMs because of anti-human antibody immune response in
mice which results in anaphylaxis. A2B5 is a mouse monoclonal
antibody that also promotes neurite outgrowth [5] and represents
a likely candidate to test single versus multiple dosing on functional
outcome and its duration of action. Finally, none of the treatments
had an effect on motor function of uninfected, normal animals.
Irrespective of the treatment all groups of normal mice showed a
gradual decline in spontaneous activity, which may be explained
by habituation to the environment. This decline of activity in
normal animals makes rHIgM12-induced increase in activity of
diseased mice even more impressive.
We have demonstrated improvement in motor function in a
chronic progressive model of inflammatory demyelinatingdisease in
which has been generally very difficult to prevent the development
of neurologic deficits. Therefore, neuron-binding monoclonal
antibody rHIgM12 represents very promising therapeutic agent
for the treatment not only of human MS, but possibly also other
demyelinating or neurodegenerative disorders. In addition, because
there are examples of clinically silent MS attacks [12,13], we and
others have proposed that neuroprotective compounds should be
complemented with immunomodulatory agents [11]. We propose
that the combined treatment of immunomodulatory drugs and
rHIgM12 may result in a significant enhancement of CNS
preservation and repair following axonal injury.
Taken together, results from this study provide three important
conclusions: 1) the stage of the disease when the treatment is given
is critical (early treatment is more beneficial); 2) to further
maintain improved motor function, there may be a need for
repeated treatments and 3) rHIgM12 is not toxic and does not
affect motor function in normal, uninfected animals. With five
mice per cage, we cannot rule out the possibility that our findings
were due to chance. The highly statistically significant differences
between the groups argue that the results are not due to chance.
Our findings were consistent across multiple experiments with
mice from different time points post infection. In addition, mice
were randomly chosen for inclusion and all had the same genetic
background. The findings are consistent with the hypothesis that a
recombinant antibody that targets neurons improve neurologic
function in a chronic axonal model of demyelination.
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